A first-in-human phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers

被引：0
|
作者：
Harding, J. [1 ]
Hofheinz, R. [2 ]
Elez, E. [3 ]
Kuboki, Y. [4 ]
Geng, J. [5 ]
Schmohl, M. [6 ]
Dowling, E. [5 ]
Feng, Y. [5 ]
Rasco, D. [7 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Univ Klinikum Mannheim, Mannheim, Germany
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Natl Canc Ctr East, Kashiwa, Chiba, Japan
[5] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[7] START Ctr Canc Care, San Antonio, TX USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-169
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [1] A phase Ia/Ib, open-label, dose-escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy in patients with advanced gastrointestinal cancers
    Kopetz, S.
    Van Cutsem, E.
    Kuboki, Y.
    Johnson, B.
    Katakabe, T.
    Geng, J.
    Archuadze, S.
    Shen, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S293 - S294
  • [2] A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Harding, James J.
    Hofheinz, Ralf-Dieter
    Elez, Elena
    Kuboki, Yasutoshi
    Rasco, Drew W.
    Cecchini, Michael
    Shen, Lin
    Dowling, Elizabeth
    Archuadze, Shorena
    de Pereira, Bruna Andrade
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [3] A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers.
    Harding, James J.
    Hofheinz, Ralf-Dieter
    Elez, Elena
    Kuboki, Yasutoshi
    Rasco, Drew W.
    Cecchini, Michael
    Shen, Lin
    He, Min
    Archuadze, Shorena
    Chhaya, Niraj
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 115 - 115
  • [4] A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Harding, J. J.
    Hofheinz, R. D.
    Fernandez, M. E. Elez
    Kuboki, Y.
    Rasco, D.
    Cecchini, M.
    Shen, L.
    Archuadze, S.
    Geng, J.
    Haderk, F.
    Pant, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S706 - S706
  • [5] A phase Ia/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours
    Sarantopoulos, J.
    Fotopoulos, G.
    Tsai, F. Y. -C.
    Beg, M. S.
    Adjei, A. A.
    Lou, Y.
    Seetharam, M.
    Villalona-Calero, M. A.
    Melear, J.
    Janat-Amsbury, M.
    Beever, H.
    Mouritsen, L.
    Wade, M.
    Bryan, B. V.
    Bearss, D. J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [7] A phase Ia/Ib, open-label, dose escalation study of the TRAILR2 agonist BI 905711 in combination with chemotherapy (CT) in patients (pts) with advanced GI cancers.
    Kopetz, Scott
    Van Cutsem, Eric
    Kuboki, Yasutoshi
    Johnson, Benny
    Katakabe, Tetsuya
    He, Min
    Archuadze, Shorena
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS820 - TPS820
  • [8] First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT901 as monotherapy in patients with select advanced solid tumors
    Harvey, R. Donald
    Falchook, Gerald Steven
    Naqash, Abdul Rafeh
    Kim, Joseph W.
    Dowlati, Afshin
    Le Bruchec, Yvan
    Coudert, Isabelle
    Ervin-Haynes, Annette L.
    Sommerhalder, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
    Lakhani, Nehal J.
    Chow, Laura Q. M.
    Gainor, Justin F.
    LoRusso, Patricia
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Bang, Yung-Jue
    Hodi, Frank Stephen
    Kim, Won Seog
    Santana-Davila, Rafael
    Fanning, Philip
    Squifflet, Pierre
    Jin, Feng
    Kuo, Tracy C.
    Wan, Hong, I
    Pons, Jaume
    Randolph, Sophia S.
    Messersmith, Wells A.
    LANCET ONCOLOGY, 2021, 22 (12): : 1740 - 1751
  • [10] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345